Back to home
DEEP DIVEApril 13, 2026·8 min read
Lilly's Oral GLP-1 and Triple Agonist Named Drugs to Watch for 2026
Clarivate highlights orforglipron (oral GLP-1) and retatrutide (GLP-1/GIP/glucagon triple agonist) as defining candidates in an obesity market projected to reach $150B by 2035. The peptide revolution accelerates.
The full analysis is published in the weekly biotech.today newsletter — subscribe for free to get the next issue in your inbox.